Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
Yoo-Na KimJe-Gun JoungEunhyang ParkJae-Weon KimJung Bok LeeJinyeong LimSunghoon KimChel Hun ChoiHee Seung KimJongsuk ChungByoung-Gie KimJung-Yun LeePublished in: International journal of cancer (2023)